186
Views
10
CrossRef citations to date
0
Altmetric
Case Series

Stickler Syndrome (SS): Laser Prophylaxis for Retinal Detachment (Modified Ora Secunda Cerclage, OSC/SS)

ORCID Icon, ORCID Icon, , , ORCID Icon, , , & show all
Pages 19-29 | Published online: 06 Jan 2021
 

Abstract

Purpose

To introduce a novel technique of encircling laser prophylaxis (ora secunda cerclage Stickler syndrome, OSC/SS) to prevent rhegmatogenous retinal detachment (RRD) in Stickler syndrome eyes.

Patients and Methods

After first eye RRD at age 50 and at age 18, respectively, a 53-year-old father and his 22-year-old son with type 2 SS (STL2) gave informed consent and underwent OSC/SS prophylaxis, performed in each fellow eye. A 26-year-old STL2 daughter then suffered first eye retinal detachment and similarly chose fellow eye OSC/SS prophylaxis. A second son, 28 years of age with STL2, chose OSC/SS prophylaxis in both eyes.

Results

The three OSC/SS treated fellow eyes have gone 12 years, 11 years, and 8 years without RRD. STL1 and less common STL2 eyes are known to have a similar rate of RRD, and 80% of STL1 fellow eyes develop RRD at a median of 4 years in the absence of prophylaxis. Moreover, five of six (83%) known STL2 family members suffered RRD, only the STL2 son with bilateral OSC/SS remaining bilaterally attached. All five OSC/SS treated eyes (average 8.7 years post-prophylaxis) retained preoperative visual acuity of 20/20 to 20/30, with an average, asymptomatic reduction of meridional field in each eye to 50 degrees. In contrast, in the three eyes having suffered RRD prior to presentation, visual acuity ranged from 20/125 to 8/200 and average meridional field was 29 degrees.

Conclusion

Encircling grid laser (OSC) modified in Stickler eyes to encompass the ora serrata and extend posteriorly to and between the vortex vein ampullae (OSC/SS) is a reasonable RRD prophylaxis option to offer STL1 and STL2 patients as an alternative to no treatment or less effective prophylaxis. Because of rarity and severity, the ultimate proof of safety and efficacy will likely come not from randomized trials, but from a non-randomized, prospective, cohort comparison study of such individual efforts.

Graphical abstract

Point your SmartPhone at the code above. If you have a QR code reader the video abstract will appear. Or use:

https://youtu.be/AzHz4xYUV_w

Data Sharing Statement

Additional material related to this article can be found at www.helenkellerfoundation.org.

Ethics and Consent Statement

This retrospective case series study was determined to be exempt from IRB approval by the Western Institutional Review Board and was conducted in accordance with the tenets of the Declaration of Helsinki for research involving human subjects. Patients provided written informed consent for their case details to be published.

Acknowledgments

As in many prior articles, the authors are grateful for excellent research, clinical, and clerical support by Christina Sullivan, Jessica Haynes, Dewayne Conn, and Laura Beckwith. C. Diane Scharper has again provided expert editing services. The authors also appreciate the supportive environment provided by the staff and physicians of Retina Specialists of Alabama and the UAB Callahan Eye Hospital.

Author Contributions

Dr. Robert Morris initally conceptualized OSC/SS, performed all treatments, and wrote the first draft. All additional authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; agreed to submit to the current journal; gave final approval of the version to be published; and agree to be accountable for all aspects of the work.

Disclosure

The authors report no conflicts of interest in this work financial or otherwise.

Additional information

Funding

Partial funding was provided by the Helen Keller Foundation for Research and Education, through grants by the Hanna Charitable Trust and the Kent Companies, and by Retina Specialists of Alabama LLC.